KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Asset Writedowns and Impairment (2018 - 2024)

Bionano Genomics recorded quarterly Asset Writedowns and Impairment of -$400000.0 in Q4 2024, down 105.56% quarter-over-quarter from $7.2 million in Q3 2024.

Bionano Genomics' Asset Writedowns and Impairment history runs 5 years deep, the most recent figure standing at -$400000.0 for Q4 2024.

  • In Q4 2024, Asset Writedowns and Impairment changed N/A year-over-year to -$400000.0; the TTM figure through Dec 2025 stood at $6.8 million (down 5.56% YoY), while the FY2024 annual figure was $7.2 million, changed N/A from the prior year.
  • Asset Writedowns and Impairment came in at -$400000.0 for Q4 2024 at Bionano Genomics, down from $7.2 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $7.2 million in Q3 2024 to a low of -$400000.0 in Q4 2024.
  • A 3-year average of $1.2 million and a median of $433000.0 in 2020 frame the typical range for Asset Writedowns and Impairment.
  • On a YoY basis, Asset Writedowns and Impairment climbed as much as 16.02% in 2020 and fell as far as 16.02% in 2020.
  • Bionano Genomics' Asset Writedowns and Impairment stood at $466000.0 in 2020, then soared by 32.19% to $616000.0 in 2022, then slumped by 164.94% to -$400000.0 in 2024.
  • According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered -$400000.0, $7.2 million, and $400000.0 for Q4 2024, Q3 2024, and Q1 2024 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Intuitive Surgical 156.17 Bn 151.78 Bn 1.83 Bn
2 Becton Dickinson 41.51 Bn 40.49 Bn 2.15 Bn
3 Resmed 30.43 Bn 28.77 Bn 890.98 Mn
4 West Pharmaceutical Services 22.78 Bn 22.26 Bn 296.40 Mn
5 Solventum 13.39 Bn 13.39 Bn 1.10 Bn
6 Cooper Companies 12.33 Bn 12.20 Bn 695.20 Mn
7 Align Technology 11.65 Bn 10.59 Bn 736.59 Mn
8 Baxter International 9.81 Bn 7.77 Bn 891.00 Mn
9 Aptargroup 7.39 Bn 7.19 Bn 351.91 Mn
10 Bionano Genomics 14.92 Mn 539,417.67 3.25 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2024 -400,000.00
Dec 31, 2024 -400,000.00
Sep 30, 2024 7.20 Mn
Sep 30, 2024 7.20 Mn
Mar 31, 2024 400,000.00
Mar 31, 2024 400,000.00
Dec 31, 2022 616,000.00
Dec 31, 2022 616,000.00
Dec 31, 2020 466,000.00
Dec 31, 2020 466,000.00
Sep 30, 2020 44,000.00
Sep 30, 2020 44,000.00
Jun 30, 2020 332,000.00
Jun 30, 2020 332,000.00
Mar 31, 2020 958,000.00
Mar 31, 2020 958,000.00
Dec 31, 2019 554,867.00
Dec 31, 2019 554,867.00
Sep 30, 2018 1.30 Mn
Sep 30, 2018 1.30 Mn